Monoclonal antibodies in the management of carcinoma patients

Mario Roselli, Carlo U. Casciani, Fiorella Guadagni, Oreste Buonomo, Beniamino Iorio, Alessandra Diodati, Vincenzo Vittorini, John W. Greiner, David Colcher, Jeffrey Schlom

Research output: Contribution to journalArticlepeer-review


The use of monoclonal antibodies (MAbs) in the clinical management of carcinoma patients is reported in the present review. Among the various MAbs generated, MAb B72.3 (LTIB, National Cancer Institute, U.S.A.) has been extensively used in clinical trials either for antigen identification (TAG-72) in sera, or for tumor localization in carcinoma patients. Serum assay results, in colorectal cancer patients, showed the usefulness of the MAb B72.3 in monitoring the clinical course of the malignant disease. Its specific tumor localization (70% of the biopsy specimens) and the immunoscintigraphy studies, after in vivo administration, have also been discussed. The positive results obtained, markedly contributed in the development of a new intraoperative methodology termed "radioimmunoguided surgery".

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalMedical Oncology and Tumor Pharmacotherapy
Issue number4
Publication statusPublished - Dec 1991


  • B72.3
  • Colorectal cancer
  • Monoclonal antibody
  • Radioimmunoguided surgery
  • TAG-72

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Monoclonal antibodies in the management of carcinoma patients'. Together they form a unique fingerprint.

Cite this